

Supporting Information for

Original Article

First small-molecule PROTACs for G protein-coupled receptors: inducing α_{1A} -adrenergic receptor degradation

Zhenzhen Li^a, Yuxing Lin^a, Hui Song^b, Xiaojun Qin^a, Zhongxia Yu^b, Zheng Zhang^a, Gaopan Dong^a, Xiang Li^a, Xiaodong Shi^c, Lupei Du^a, Wei Zhao^b, Minyong Li^{a,d,*}

^a*Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE), School of Pharmacy, Shandong University, Jinan 250012, China*

^b*Department of Immunology, Key Laboratory of Infection and Immunity of Shandong Province, School of Basic Medical Science, Shandong University, Jinan 250012, China*

^c*Department of Chemistry, University of South Florida, Tampa, FL 33620, USA*

^d*State Key Laboratory of Microbial Technology, Shandong University, Jinan 250100, China*

Received 19 September 2019; received in revised form 18 November 2019; accepted 26 December 2019

*Corresponding author. Tel./fax: +86 531 88382076.

E-mail address: mli@sdu.edu.cn (Minyong Li).

Table of contents

Figure S1 The cytotoxicity of compounds	S2
Figure S2 The effects of compound 9c on the level of α_{1B} -AR and α_{1D} -AR	S2
Figure S3 Docking model of the compound 9c bound to DDB1-CRBN	S3
Figure S4 Photograph of nude mice	S3
NMR, MS and HRMS data of compounds	S4
HPLC data of final compounds.....	S17




Figure S1 The cytotoxicity of compounds, 0–200 μmol/L.




Figure S2 The effects of compound **9c** on the level of α_{1B} -AR and α_{1D} -AR. The cells were treated with compound **9c** as indicated for 12 h before harvesting and then analyzed by Western blotting.




Figure S3 (A) Binding sites of the hydrogen bonds between compound **9c** and CRBN. Compound **9c** is highlighted in the green stick. The dimer forming the cap for the binding pocket is colored in light yellow. Black dash lines represent the key hydrogen bonds. (B) Docking model of the compound **9c** bound to DDB1-CRBN (PDB: 4CI3).












Figure S4 The nude mice with the PC-3 derived prostate cancer xenografts were photographed after two weeks of intraperitoneal administration.



NMR, MS and HRMS data of compounds





































HPLC data of final compounds




Peak	Retention time (min)	Peak types	Peak width	Peak area	Peak height	Peak area (%)
1	2.263	BB	0.1160	22.53704	2.98896	1.4953
2	2.821	BB	0.1452	19.77697	1.78535	1.3122
3	13.762	BB	0.3518	1464.83813	58.56503	97.1925

HPLC analysis of compound **9a**.



Peak	Retention time (min)	Peak types	Peak width	Peak area	Peak height	Peak area (%)
1	2.113	BV	0.1349	46.53817	5.17572	2.1330
2	2.771	BB	0.1574	50.87490	4.25820	1.3317
3	7.326	BB	0.2046	19.47536	1.23116	0.8926
4	14.454	BB	0.4568	2064.94604	64.96188	95.6427

HPLC analysis of compound **9b**.



Peak	Retention time (min)	Peak types	Peak width	Peak area	Peak height	Peak area (%)
1	1.801	BV	0.0785	6.08178	1.17374	0.3082
2	2.266	BB	0.1211	19.89354	2.49283	1.0083
3	2.827	BB	0.1618	33.25452	2.77606	1.6854
4	13.762	BB	0.3467	1913.82581	77.88319	96.9981

HPLC analysis of compound **9c**.